10,11-Seco-LSD, also known as UCD0121, is a partial lysergamide and cyclized tryptamine related to lysergic acid diethylamide (LSD). It is the seco analogue of LSD in which the bond between the 10 and 11 positions of the ergoline ring system has been broken. 10,11-Seco-LSD was described in a patent by David E. Olson and colleagues at Delix Therapeutics in 2021. Subsequently, 10,11-seco-LSD was further described by Olson and colleagues in the scientific literature in 2026.
See also Partial lysergamide Seco-LSD Secoergoline NDTDI (8,10-seco-LSD) UCD0179 (3,5-seco-LSD) Mefloquine
References